| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/01/2005 | WO2004096159A3 Saposin c-dops: a novel anti-tumor agent |
| 09/01/2005 | WO2004078992A3 Methods for the identification of inhibitors of pyrroline-5-carboxylate reductase as antibiotics |
| 09/01/2005 | WO2004076639A8 Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| 09/01/2005 | WO2004072282A9 Nephropathy-associated gene |
| 09/01/2005 | WO2004060911A3 Combination therapy with co-stimulatory factors |
| 09/01/2005 | WO2004056310A3 Methods of diagnosis and treatment of interstitial lung disease |
| 09/01/2005 | WO2004053060A3 ANTISENSE MODULATION OF mitoNEET EXPRESSION |
| 09/01/2005 | WO2004048512A3 Novel proteins and nucleic acids encoding same |
| 09/01/2005 | WO2004024076A8 Novel compositions and methods for the treatment of immune related diseases |
| 09/01/2005 | WO2004020405A3 Modified transferrin fusion proteins |
| 09/01/2005 | WO2004003162A3 Enzymes |
| 09/01/2005 | WO2004003140A3 Cytokine receptor zcytor17 multimers |
| 09/01/2005 | WO2003018759A3 Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| 09/01/2005 | WO2002083873A3 Enzymes |
| 09/01/2005 | US20050192647 Electrical devices and anti-scarring agents |
| 09/01/2005 | US20050192494 System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
| 09/01/2005 | US20050192443 Synergistic mixture of animal bile extract and anticancer agents; modulate releasing of tumor necrosis factor, interleukins, colony stimulating factor |
| 09/01/2005 | US20050192428 Modified procollagen comprising collagen peptide chain and site-specific proteolytic agent recognition site for use preparation of biodegradable surical materials |
| 09/01/2005 | US20050192353 Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
| 09/01/2005 | US20050192327 Myocardial infarction or its recurrence is treated with telmisartan an ACE inhibitor |
| 09/01/2005 | US20050192326 Treating stroke or reccurence with an ACE inhibitor selected from quinapril, captropril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, delapril, moveltipril and trandolapril |
| 09/01/2005 | US20050192299 Method of treating or preventing hepatitis B virus |
| 09/01/2005 | US20050192269 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 09/01/2005 | US20050192261 Methods and reagents for the treatment of immunoinflammatory disorders |
| 09/01/2005 | US20050192259 A sustained release formulation of an aldosterone antagonist orally administered about 6-12 hours prior to the acrophase to provide a profile of plasma drug concentration corresponding to the diurnal cycle of plasma aldosterone concentration; hypotensive agents; circadi rhythm; cardiovascular disorders |
| 09/01/2005 | US20050192243 Neuromuscular blocking agents and antagonists thereof |
| 09/01/2005 | US20050192241 Administering to the joint having systemic onset juvenile idiopathic arthritis an active agent that will reduce the bioavailability of interleukin-1 beta (IL-1 beta) by modifying the transcription, translation or gene expression or by blocking the IL-1 beta recepter;antiinflammatory agent; antipyretics |
| 09/01/2005 | US20050192238 Modulation of the expression of genes dependent on stat-1 |
| 09/01/2005 | US20050192237 Antisense antibacterial cell division composition and method |
| 09/01/2005 | US20050192232 E.g.,N[(R)-3-dodecanoyloxytetradecanoylamino]-C-aspartic acid, alpha-N-{(4R)-5-hydroxy-4-[(R)-3-hydroxytetradecanoyl- amino]pentyl}amide; grafting antigens to modulate immune response and on a pharmaceutical carrier or antibiotic to enhance therapeutic effect or targetting aqueous conjugate injections |
| 09/01/2005 | US20050192231 Treating hepatitis with a cytoprotective agents such as benzyloxycarbonyl-valine-aspartic acid(methyl ester)-methyl fluoride or having leucine and isoleucine as replacements for valine; caspase enzyme inhibitors; fas antigen suppressors; neuroprotective agents; antiischemic agents; organ transplants |
| 09/01/2005 | US20050192230 Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine |
| 09/01/2005 | US20050192229 Treating psoriasis by topically applying to the affected skin areas a high concentration (40-60%) of reduced glutathione; alpha lipoic acid as an adjuvant along with a carrier; antiinflammatory agents; antiallergens; eczema; seborrhea dematitus; roazcea; acne; skin disorders |
| 09/01/2005 | US20050192228 A cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide and cinnamoyl-isoleucyl-isoleucyl-prolineamide; apoptosis resistance; reversing of nerve degeneration, particularly of hippocampal cells Alzheimer's and Parkinson's disease; congnition activators |
| 09/01/2005 | US20050192227 Method for reducing the risk of cancer |
| 09/01/2005 | US20050192226 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| 09/01/2005 | US20050192225 Methods for treating Parkinson's disease |
| 09/01/2005 | US20050192224 Modulation platelet adhesion based on the surface-exposed beta-switch loop of platelet glycoprotein IB-alpha |
| 09/01/2005 | US20050192223 Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin |
| 09/01/2005 | US20050192222 Pharmaceutical preparations and medicine capable of generating and/or containing thrombin |
| 09/01/2005 | US20050192221 Antimicrobial/immune modulatory agent comprising all or part of a polypeptide having an amino acid sequence of SPLUNC1, LPLUNC1, or both, and pharmaceutically acceptable carrier (PLUNC for palate, lung, and nasal epithelium clone); anti-inflammatory agents, respiratory system disorders |
| 09/01/2005 | US20050192219 Therapies involving mutated heat shock transcription factor |
| 09/01/2005 | US20050192218 For producing analgesia in a mammalian subject |
| 09/01/2005 | US20050192217 Utilization of lipopeptides or lipoproteins in wound treatment and infection prophylaxis |
| 09/01/2005 | US20050192216 Freeze- or vacuum-dried native Factor VIII composition containing trehalose as a stabilizer and no albumin; may be reconstituted with water or brine for administration to a hemophilic patient by injection; stable at up to 60 degrees C. |
| 09/01/2005 | US20050192215 Methods and materials relating to novel polypeptides and polynucleotides |
| 09/01/2005 | US20050192214 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 09/01/2005 | US20050192213 Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| 09/01/2005 | US20050192212 Viricides; induction immunology response; compounds according to invention specifically inhibit NS3 protease and do not show significant inhibitory activity against other serine proteases such as human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, or cysteine proteases |
| 09/01/2005 | US20050192211 Fc-erythropoietin fusion protein with improved pharmacokinetics |
| 09/01/2005 | US20050192210 Treating or preventing vascular condition in patient by administering locally a therapeutically effective amount of a composition that increases metabolic production of nitric oxide by nitric oxide synthases; treatment of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease |
| 09/01/2005 | US20050192209 Eosinophil Major Basic Protein as a natural heparanase-inhibiting protein, compositions, methods and uses thereof |
| 09/01/2005 | US20050191742 Trophoblast cell preparations |
| 09/01/2005 | US20050191737 Carcinostatic agent |
| 09/01/2005 | US20050191729 Methods for the recombinant production of antifusogenic peptides |
| 09/01/2005 | US20050191724 Nematode-extracted serine protease inhibitors and anticoagulant proteins |
| 09/01/2005 | US20050191713 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 09/01/2005 | US20050191703 Bioassy for identifying compounds which prevent host proteins interation with viral protein associated with infection, replication, assembly or release; viricides |
| 09/01/2005 | US20050191702 Immunoglobulin comprising chemokine receptor binding domain and T cell surface polypeptide for use in prevention and treatment of nervous system, skin, diabetes, graft versus host, inflammatory joint and autoimmune diseases |
| 09/01/2005 | US20050191696 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products |
| 09/01/2005 | US20050191690 Membrane proteins for identifying modulators for prevention and treatment of infection, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders |
| 09/01/2005 | US20050191681 Nucleotide sequences coding secretory proteins for use in diagnosis, prevention and treatment of nervous system, inflammatory, cell proliferative, cardiovascular and blood disorders |
| 09/01/2005 | US20050191671 Transport protein peptide related to sodium/hydrogen exchanger-regulatory factors for use in identifying modulators for prevention and treatment of nervous system and cell proliferative disorders; antiproliferative agents |
| 09/01/2005 | US20050191668 Methods of using peroxisome proliferator-activated receptor alpha target genes |
| 09/01/2005 | US20050191667 Using mutant mannose-binding lectin gene as diagnostic indicator of vaginal urogenital disorders |
| 09/01/2005 | US20050191661 Treatment of inflammatory disease by cleaving TNF receptors |
| 09/01/2005 | US20050191650 Used to reduce body temperature, suppress appetite, and therapy or prophylaxis of congestive heart failure and various stress-related disorders |
| 09/01/2005 | US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders |
| 09/01/2005 | US20050191641 Nucleotide sequences coding hydrolase for use as tool in identifying modulators for prevention and treatment of digestion, coagulation, diabetic, cell proliferative, urogenital, eating and nervous system gynecological disorders |
| 09/01/2005 | US20050191638 Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy |
| 09/01/2005 | US20050191635 Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same |
| 09/01/2005 | US20050191633 Isolated from Bacillus substilus; immunogens; solid phase synthesis; reverse transcription; kits |
| 09/01/2005 | US20050191621 CD4-independent HIV envelope proteins as vaccines and therapeutics |
| 09/01/2005 | US20050191403 Palliative treatment for gluten intolerance |
| 09/01/2005 | US20050191385 Phyto-derived tetracyclic compounds with steroidal-like activity |
| 09/01/2005 | US20050191367 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors |
| 09/01/2005 | US20050191364 Use of enhanced water to improve blood sugar management |
| 09/01/2005 | US20050191360 Dry powder inhaled PTH formulations; Dipalmitoylphosphatidylcholine and sodium citrate; Parathyroid hormone; maintainence of parathyroid hormone chemical stability |
| 09/01/2005 | US20050191342 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 09/01/2005 | US20050191331 e.g. central nervous system shunt; antiscarring agent such as an angiogenesis inhibitor to inhibit scarring between the implant and a host |
| 09/01/2005 | US20050191321 Combination of local botulinum toxin and oral triptan drug administration; preventing overuse; reducing pain sensory output |
| 09/01/2005 | US20050191320 Local delivery of botulinum toxin to target area; headaches, acute and chronic pain |
| 09/01/2005 | US20050191316 Neisseria genomic sequences and methods of their use |
| 09/01/2005 | US20050191315 Identification of epitopes on staphylococcal enterotoxins |
| 09/01/2005 | US20050191314 vaccine comprosing a mixture of A beta oligomers capable of generating an immune response; prophylaxis and treatment of Alzheimer's disease |
| 09/01/2005 | US20050191312 Diagnosis by detecting overexpression; active or passive immunization; antibodies, transgenic animals, hybridoma |
| 09/01/2005 | US20050191309 Induction of antigen specific immunologic tolerance |
| 09/01/2005 | US20050191307 Novel multidrug resistance-associated polypeptide |
| 09/01/2005 | US20050191304 Employing Zvegf3 antagonists |
| 09/01/2005 | US20050191303 Interleukin-18-binding protein |
| 09/01/2005 | US20050191302 Administering an inducer (sulfasalazine) of hepatic stellate cell apoptosis; selective delivery; fibrosis; inhibiting interaction of a tissue inhibitor of a matrix metalloprotease (TIMP) with a matrix metalloprotease |
| 09/01/2005 | US20050191301 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses |
| 09/01/2005 | US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 09/01/2005 | US20050191292 of reversing cognitive decline by administering a humanized antibody that binds to A beta; particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease or Down's syndrome. |
| 09/01/2005 | US20050191288 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient |
| 09/01/2005 | US20050191285 Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
| 09/01/2005 | US20050191284 Which lack potential to differentiate into myeloid and erythroid lineages; interleukins; stem cell factors; natural killer cells |
| 09/01/2005 | US20050191283 Methods of treating NFAT-related disorders |
| 09/01/2005 | US20050191277 Methods of treating various cancers using melanoma differentiation associated protein-7 |
| 09/01/2005 | US20050191276 Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase |